BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 29771293)

  • 1. Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole.
    Rausch CR; DiPippo AJ; Bose P; Kontoyiannis DP
    Clin Infect Dis; 2018 Oct; 67(10):1610-1613. PubMed ID: 29771293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breakthrough Invasive Fungal Infections on Isavuconazole Prophylaxis and Treatment: What Is Happening in the Real-World Setting?
    Fung M; Schwartz BS; Doernberg SB; Langelier C; Lo M; Graff L; Tan M; Logan AC; Chin-Hong P; Babik JM
    Clin Infect Dis; 2018 Sep; 67(7):1142-1143. PubMed ID: 29617983
    [No Abstract]   [Full Text] [Related]  

  • 3. [Current therapeutic options in invasive mycosis and potential therapeutic role of isavuconazole].
    Garcia-Vidal C
    Rev Iberoam Micol; 2018; 35(4):192-197. PubMed ID: 30455108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isavuconazole for the prophylaxis and treatment of invasive fungal disease: A single-center experience.
    Vu CA; Rana MM; Jacobs SE; Saunders-Hao P
    Transpl Infect Dis; 2021 Apr; 23(2):e13469. PubMed ID: 32946658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib.
    Cummins KC; Cheng MP; Kubiak DW; Davids MS; Marty FM; Issa NC
    Leuk Lymphoma; 2019 Feb; 60(2):527-530. PubMed ID: 30037292
    [No Abstract]   [Full Text] [Related]  

  • 6. Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity.
    Ledoux MP; Denis J; Nivoix Y; Herbrecht R
    J Mycol Med; 2018 Mar; 28(1):15-22. PubMed ID: 29551442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and effectiveness of isavuconazole in real-life non-neutropenic patients.
    Monzó-Gallo P; Lopera C; Badía-Tejero AM; Machado M; García-Rodríguez J; Vidal-Cortés P; Merino E; Calderón J; Fortún J; Palacios-Baena ZR; Pemán J; Sanchis JR; Aguilar-Guisado M; Gudiol C; Ramos JC; Sánchez-Romero I; Martin-Davila P; López-Cortés LE; Salavert M; Ruiz-Camps I; Chumbita M; Aiello TF; Peyrony O; Puerta-Alcalde P; Soriano A; Marco F; Garcia-Vidal C
    Int J Infect Dis; 2024 Jul; 144():107070. PubMed ID: 38663477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.
    Stern A; Su Y; Lee YJ; Seo S; Shaffer B; Tamari R; Gyurkocza B; Barker J; Bogler Y; Giralt S; Perales MA; Papanicolaou GA
    Biol Blood Marrow Transplant; 2020 Jun; 26(6):1195-1202. PubMed ID: 32088367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system.
    Schwartz S; Cornely OA; Hamed K; Marty FM; Maertens J; Rahav G; Herbrecht R; Heinz WJ
    Med Mycol; 2020 Jun; 58(4):417-424. PubMed ID: 31613363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species.
    Marty FM; Cornely OA; Mullane KM; Ostrosky-Zeichner L; Maher RM; Croos-Dabrera R; Lu Q; Lademacher C; Oren I; Schmitt-Hoffmann AH; Giladi M; Rahav G; Perfect JR
    Mycoses; 2018 Jul; 61(7):485-497. PubMed ID: 29611227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Invasive aspergillosis in solid organ transplantation].
    Silva JT; Torre-Cisneros J; Aguado JM
    Rev Iberoam Micol; 2018; 35(4):206-209. PubMed ID: 30467000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center.
    Van Matre ET; Evans SL; Mueller SW; MacLaren R; Fish DN; Kiser TH
    Ann Clin Microbiol Antimicrob; 2019 Mar; 18(1):13. PubMed ID: 30894179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isavuconazole: A New Option for the Management of Invasive Fungal Infections.
    Pettit NN; Carver PL
    Ann Pharmacother; 2015 Jul; 49(7):825-42. PubMed ID: 25940222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.
    Kovanda LL; Marty FM; Maertens J; Desai AV; Lademacher C; Engelhardt M; Lu Q; Hope WW
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis.
    Cheng MP; Orejas JL; Arbona-Haddad E; Bold TD; Solomon IH; Chen K; Pandit A; Kusztos AE; Cummins KC; Liakos A; Marty FM; Koo S; Hammond SP
    Mycoses; 2020 Jan; 63(1):58-64. PubMed ID: 31587405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial.
    Perfect JR; Cornely OA; Heep M; Ostrosky-Zeichner L; Mullane KM; Maher R; Croos-Dabrera R; Lademacher C; Engelhardt M; Chen C; Marty FM
    Mycoses; 2018 Jul; 61(7):420-429. PubMed ID: 29570857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom.
    Floros L; Pagliuca A; Taie AA; Weidlich D; Rita Capparella M; Georgallis M; Sung AH
    J Med Econ; 2020 Jan; 23(1):86-97. PubMed ID: 31262225
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.
    Floros L; Kuessner D; Posthumus J; Bagshaw E; Sjölin J
    BMC Infect Dis; 2019 Feb; 19(1):134. PubMed ID: 30744563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.
    Murrell D; Bossaer JB; Carico R; Harirforoosh S; Cluck D
    Int J Pharm Pract; 2017 Feb; 25(1):18-30. PubMed ID: 27569742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials.
    Andes DR; Ghannoum MA; Mukherjee PK; Kovanda LL; Lu Q; Jones ME; Santerre Henriksen A; Lademacher C; Hope WW
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.